Matt Lucas sits on steps outdoors while looking contemplatively.

Matt Lucas

Chief Scientific Officer

As Chief Scientific Officer, Matt Lucas has more than 20 years of drug discovery experience. He was most recently Senior Vice President of Drug Discovery at Black Diamond Therapeutics where he led the CNS-penetrant EGFR mutant inhibitor program that delivered BDTX-1535, currently in a Phase I clinical trial for GBM and NSCLC. Earlier, he served in leadership roles at Yumanity Therapeutics, Cubist Pharmaceuticals and at Roche, leading multiple projects from discovery to clinical development in numerous therapeutic areas including oncology, immunology and neuroscience. Matt earned his Ph.D. in Chemistry and Biochemistry from the University of Southampton, UK, and completed postdoctoral research at Florida State University.